Mathai Mammen is SVP & Research & Early Clin Dev at THERAVANCE INC (THRX). They have made 1 open-market trade across 1 company since 2010, most recently 2024-06-11.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TXG | SELL | 2023-05-11 | 2023-05-15 | $52.82 | $1.7M | -3.1% | +8.9% | -5.2% |
| THRX | SELL · 10b5-1 | 2014-02-14 | 2014-02-19 | $39.36 | $1.4M | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2013-07-30 | 2013-08-01 | $36.51 | $256K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2013-04-30 | 2013-05-02 | $33.74 | $236K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2013-02-20 | 2013-02-22 | $22.14 | $155K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2012-11-02 | 2012-11-06 | $21.45 | $150K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2012-08-13 | 2012-08-15 | $25.74 | $643K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2011-02-18 | 2011-02-23 | $23.12 | $86K | -6.0% | -1.1% | -1.1% |
| THRX | SELL · 10b5-1 | 2010-09-01 | 2010-09-02 | $12.84 | $57K | -6.0% | -1.1% | -1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.